COLLPLANT HOLDI/S (NASDAQ: CLGN) is one of 27 public companies in the “Surgical appliances & supplies” industry, but how does it contrast to its peers? We will compare COLLPLANT HOLDI/S to related businesses based on the strength of its analyst recommendations, dividends, profitability, institutional ownership, risk, valuation and earnings.
This is a breakdown of current ratings and target prices for COLLPLANT HOLDI/S and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|COLLPLANT HOLDI/S Competitors||172||816||1439||73||2.57|
Earnings and Valuation
This table compares COLLPLANT HOLDI/S and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|COLLPLANT HOLDI/S||$480,000.00||-$6.02 million||-2.45|
|COLLPLANT HOLDI/S Competitors||$1.30 billion||$195.91 million||23.18|
COLLPLANT HOLDI/S’s peers have higher revenue and earnings than COLLPLANT HOLDI/S. COLLPLANT HOLDI/S is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
58.0% of shares of all “Surgical appliances & supplies” companies are held by institutional investors. 9.9% of shares of all “Surgical appliances & supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares COLLPLANT HOLDI/S and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|COLLPLANT HOLDI/S Competitors||-184.55%||-204.58%||-24.01%|
COLLPLANT HOLDI/S peers beat COLLPLANT HOLDI/S on 8 of the 9 factors compared.
About COLLPLANT HOLDI/S
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company's products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.
Receive News & Ratings for COLLPLANT HOLDI/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for COLLPLANT HOLDI/S and related companies with MarketBeat.com's FREE daily email newsletter.